Letrozole as a Treatment of Endometrial Cancer

Completed · Not applicable

Conditions studied: Endometrial Carcinoma

In brief

Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.

Key facts

Study ID

NCT00997373

Run by

University of California, Davis

People needed

43

Starts

2009-10-01

Expected to finish

2013-09-01

Last updated by the study team

2017-05-30

Who can join

Age: 40 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium
• Post menopausal status must be demonstrated
• Signed informed consent

You may not qualify if…

• FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the endometrium
• Younger than 40 or postmenopausal status not established
• Pregnant or breastfeeding

Where it is running

• University of California Davis — Sacramento, California, United States
• University of California, Davis — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.